GLP-1 medications are changing the way employers approach employee healthcare benefits. Originally developed to help manage type 2 diabetes, certain GLP-1-based treatments are now approved for weight management and other medical conditions, creating new opportunities for employee health while introducing financial challenges for employer-sponsored health plans.
Medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have attracted significant attention. However, their growing use raises an important question for human resources professionals: How can employers provide access to effective treatments without allowing prescription drug costs to overwhelm their benefits budgets?
According to the 2026 KFF Employer Health Benefits Survey, 33% of employers with 5,000 or more workers covered GLP-1 medications primarily for weight loss. Among employers of that size providing coverage, 61% reported a significant impact on prescription drug spending.
These findings highlight why GLP-1 coverage has become an important consideration for HR leaders, benefits managers, and finance teams.
Here are 10 essential things HR professionals should know about managing GLP-1 costs in employee health plans.
1. Understand What GLP-1 Medications Cover and Why Costs Are Rising
Before making coverage decisions, HR teams need to understand the different medical uses of GLP-1 medications.
GLP-1 receptor agonists mimic a hormone involved in regulating blood sugar, appetite, and digestion. Some newer treatments also act on additional hormone receptors.
These medications are prescribed for several conditions, depending on the specific drug and its FDA-approved indications.
Common examples include:
- Ozempic (semaglutide): Primarily used for type 2 diabetes, with additional approved indications for certain patients.
- Wegovy (semaglutide): Approved for chronic weight management and certain other conditions.
- Mounjaro (tirzepatide): Used to improve blood sugar control in people with type 2 diabetes.
- Zepbound (tirzepatide): Approved for chronic weight management and moderate-to-severe obstructive sleep apnea in certain adults.
- Wegovy tablets and Foundayo (orforglipron): Oral weight-management options approved in December 2025 and April 2026, respectively.
Not all medications containing the same active ingredient have identical approved uses.
For employers, this distinction matters because a health plan may cover a medication for diabetes while excluding the same or a related medication when prescribed for weight management.
What HR should do: Work with the benefits administrator or pharmacy benefit manager (PBM) to understand which medications are covered, for which diagnoses, and under what conditions.
2. Build a Realistic GLP-1 Cost Forecast Before Expanding Coverage
One of the biggest mistakes employers can make is evaluating GLP-1 coverage using only the price of an individual prescription.
Total spending depends on how many employees and dependents qualify, how many start treatment, how long they remain on medication, and how much the health plan actually pays.
HR teams should work with finance departments and benefits consultants to model multiple scenarios.
For example, consider a hypothetical employer with 1,000 covered members.
If 5% of covered members use a GLP-1 medication and the plan’s average net monthly cost is $500 per user, annual drug spending would be:
50 members × $500 × 12 months = $300,000 annually.
This is an illustrative calculation, not an industry-average cost estimate. Actual expenses depend on negotiated prices, rebates, utilization, treatment duration, and member cost-sharing.
A comprehensive financial forecast should also consider future demand, new medication approvals, and changes in treatment patterns.
Employers should avoid assuming that potential reductions in diabetes-related or cardiovascular healthcare expenses will immediately offset medication spending. Clinical benefits can be substantial, but short-term financial savings are not guaranteed.
What HR should do: Request low-, moderate-, and high-utilization cost projections before making annual benefits decisions.
3. Review Pharmacy Benefit Manager Contracts and Drug Pricing
Pharmacy benefit managers play an important role in determining prescription drug costs for employer-sponsored health plans.
However, the amount an employer pays can differ significantly from a medication’s advertised list price.
Pricing arrangements may involve manufacturer rebates, negotiated discounts, pharmacy reimbursement rates, administrative fees, and other contract provisions.
HR leaders should understand the difference between gross prescription spending and the employer’s actual net cost.
When reviewing a PBM contract, employers should ask whether rebates are fully passed through, how administrative fees are calculated, which medications receive preferred formulary placement, and whether lower-net-cost alternatives are available.
It is also important to examine whether specialty medication spending could trigger additional fees or affect future contract pricing.
New oral medications and manufacturer-direct purchasing programs add more options to the market, but a lower advertised cash price does not automatically translate into lower overall health-plan spending.
What HR should do: Compare PBM proposals using estimated net plan costs, not just rebates or headline discounts.
4. Use Prior Authorization Without Creating Unnecessary Barriers
Prior authorization can help employers manage GLP-1 spending by confirming that a prescribed medication meets the plan’s coverage requirements.
Depending on the medication and approved indication, these requirements may consider clinical diagnoses, medical history, established treatment guidelines, and other relevant factors.
For weight-management coverage, some plans use body mass index (BMI) and related health conditions as part of eligibility determinations.
However, excessive administrative requirements can delay clinically appropriate treatment and frustrate employees.
HR teams should aim for a balance between responsible spending and reasonable access.
The 2026 KFF survey found that 40% of employers with 200 or more workers covering GLP-1s for weight loss required participation in a lifestyle program or contact with a healthcare professional as a coverage condition.
Such programs may provide valuable support, but they should be designed around clinical needs rather than serving only as an obstacle to obtaining medication.
Employers should also verify that appeals and exceptions processes are available when medically appropriate.
What HR should do: Review prior authorization criteria with clinical experts and ensure employees understand the approval and appeal process.
5. Prepare for Long-Term Treatment Costs
GLP-1 treatment is not always a short-term expense.
For some patients, obesity and related metabolic conditions require ongoing medical management. This creates a financial challenge because prescription costs may continue for multiple years.
Research also indicates that stopping treatment can result in weight regain.
A clinical trial extension published in Diabetes, Obesity and Metabolism found that participants who discontinued semaglutide treatment regained approximately two-thirds of their previous weight loss over the following year.
This does not mean every employee will require lifelong treatment. Decisions about continuation, adjustment, or discontinuation should remain with qualified healthcare professionals.
Nevertheless, employers should avoid financial projections that assume most employees will complete treatment within a few months.
HR and benefits teams should consider treatment persistence, ongoing monitoring, changes in medication, and the potential implications of stopping coverage.
What HR should do: Include multi-year cost projections in benefits planning and establish clear policies for employees already receiving treatment when coverage changes.
6. Combine Medication Coverage With Comprehensive Health Support
GLP-1 medications should not be viewed as a replacement for broader employee health and wellness programs.
Employees using these treatments may also benefit from nutritional counseling, physical activity support, behavioral healthcare, and chronic disease management.
An integrated healthcare approach can support safe treatment and help employees develop sustainable habits.
Employers can explore partnerships with qualified healthcare providers offering services such as dietary guidance, diabetes education, and medically supervised weight-management programs.
These services may help address health needs beyond prescription medication alone.
However, HR teams should evaluate whether additional programs provide meaningful support instead of simply adding another vendor fee to an already expensive benefit.
Not every employee needs the same services, and treatment decisions should be individualized.
What HR should do: Evaluate GLP-1 coverage alongside existing wellness and chronic disease programs to identify gaps, unnecessary duplication, and opportunities for coordinated care.
7. Understand Legal Compliance and Employee Privacy Requirements
GLP-1 benefits involve more than prescription costs. They can also raise important compliance and privacy questions.
Employer-sponsored health plans must operate within applicable federal and state requirements, including relevant provisions of the Employee Retirement Income Security Act (ERISA), Health Insurance Portability and Accountability Act (HIPAA), and Affordable Care Act (ACA).
Although private employer health plans generally have discretion over whether to cover medications specifically for weight management, coverage decisions must still comply with applicable legal requirements and the plan’s governing documents.
Programs that condition incentives or benefits on health-related activities may also trigger wellness-program nondiscrimination rules.
HR teams should be particularly careful when collecting or accessing sensitive information, including an employee’s diagnosis, weight, medication use, or treatment progress.
Individual medical information should be handled by authorized healthcare and benefits professionals rather than unnecessarily shared with workplace managers.
Employers introducing separate reimbursement programs or direct-to-consumer arrangements should also examine whether these create additional group health plan, tax, or reporting obligations.
What HR should do: Have benefits counsel review plan design, privacy practices, wellness requirements, vendor agreements, and employee communications before implementing substantial coverage changes.
8. Evaluate Direct-to-Consumer Programs and Alternative Purchasing Models
Traditional employer health plans are no longer the only pathway employees may use to access GLP-1 medications.
Manufacturer-direct programs, telehealth providers, and other purchasing models have introduced additional options.
The International Foundation of Employee Benefit Plans’ 2026 GLP-1 survey reported that 27% of surveyed employers encouraged employees to obtain GLP-1 medications through direct-to-consumer platforms.
For some employees, these arrangements may offer lower cash prices or greater convenience.
However, affordability is only one consideration.
Employers should evaluate whether a program uses FDA-approved medications, provides appropriate clinical oversight, protects health information, and clearly explains its pricing.
Special caution is appropriate with compounded GLP-1 products. The FDA warns that compounded medications are not FDA-approved and must comply with applicable compounding restrictions.
HR should also verify whether employees can use health savings accounts (HSAs), flexible spending accounts (FSAs), or health reimbursement arrangements (HRAs) for a proposed purchasing model. Tax eligibility and plan compatibility depend on the specific circumstances.
What HR should do: Compare alternative purchasing arrangements on total cost, clinical safety, legal compliance, employee experience, and continuity of care.
9. Measure the Actual Value of GLP-1 Benefits
A successful GLP-1 strategy should measure more than the number of prescriptions filled.
Employers need to understand whether their coverage approach is financially sustainable, clinically appropriate, and valuable to employees.
Useful measures include overall prescription spending, medication utilization trends, adherence and discontinuation patterns, prior authorization outcomes, employee out-of-pocket expenses, and satisfaction with benefits.
Where reliable aggregated data is available, employers can also evaluate longer-term trends in related healthcare utilization.
However, changes in healthcare spending or employee productivity should not automatically be attributed to GLP-1 treatment. Many other factors can influence these outcomes.
Employers should also consider that measurable health improvements may emerge over a longer period than the annual benefits budgeting cycle.
A quarterly review can identify unexpected utilization or spending changes, while an annual evaluation can support broader coverage decisions.
What HR should do: Establish a small benefits performance dashboard with finance, the insurer or third-party administrator, and the PBM. Review aggregated results without exposing individual employee medical information.
10. Communicate Coverage Decisions Clearly and Compassionately
Even a carefully designed benefits strategy can fail if employees do not understand what their health plan covers.
GLP-1 medications have become a highly visible topic, and employees may assume that popular treatments are automatically included in their prescription benefits.
HR departments should provide straightforward explanations of medication eligibility, covered indications, prior authorization rules, cost-sharing responsibilities, and available support.
Communication becomes particularly important when an employer introduces new restrictions, changes preferred medications, or discontinues coverage for a particular indication.
Employees already receiving treatment may need time to consult their healthcare providers and understand alternative coverage or treatment options.
Poor communication can result in unexpected expenses, treatment interruptions, and reduced confidence in employer benefits.
Sensitive discussions should also avoid assumptions about an employee’s weight, lifestyle, or medical circumstances.
Employers should use respectful, non-stigmatizing language and ensure that employees know whom to contact for confidential benefits assistance.
What HR should do: Include a dedicated GLP-1 coverage explanation in open enrollment materials and provide confidential support for questions about eligibility, costs, and appeals.
How HR Teams Can Build a Sustainable GLP-1 Cost Management Strategy
Managing GLP-1 spending requires coordination between HR, finance teams, insurers, benefits consultants, healthcare providers, and pharmacy benefit managers.
A practical strategy should answer five key questions:
- Which FDA-approved indications and medications will the health plan cover?
- What are the expected short-term and long-term costs?
- Which clinically appropriate cost-management measures should be introduced?
- How will employees receive information and access support?
- Which financial, clinical, and employee-experience measures will determine whether the strategy is working?
Employers do not necessarily need to offer identical coverage arrangements. The appropriate approach depends on workforce needs, organizational budgets, existing benefits, and applicable legal requirements.
Some employers may offer broader coverage with clinical management. Others may prioritize coverage for specific medical indications while assessing additional options for weight management.
The key is to make deliberate, evidence-informed decisions instead of reacting only to prescription spending increases.
Final Thoughts
GLP-1 medications represent an important development in the treatment of diabetes, obesity, and certain related medical conditions. For employers, they also introduce a complex benefits-management challenge.
The goal should not be simply to minimize prescription spending. It should be to build a healthcare benefits strategy that balances affordability, clinical effectiveness, employee access, and long-term sustainability.
By reviewing PBM contracts, forecasting utilization, understanding coverage requirements, monitoring costs, and communicating transparently, HR professionals can make more informed decisions about these increasingly important medications.
As new treatments, pricing arrangements, and coverage options continue to emerge, employers that regularly review their GLP-1 benefits strategy will be better positioned to control costs while supporting workforce health.
For HR leaders, effective GLP-1 cost management is ultimately about making employee health benefits sustainable without losing sight of the people those benefits are designed to serve.
Frequently Asked Questions
1. Are employers required to cover GLP-1 medications for weight loss?
Private employer-sponsored health plans are generally not required to cover GLP-1 medications solely for weight management. However, requirements can vary based on applicable laws, plan type, specific medical indications, and plan documents. Employers should consult benefits counsel before excluding or changing coverage.
2. Why are GLP-1 medications expensive for employer health plans?
Costs can increase because of medication prices, the number of eligible members, long-term treatment needs, and growing utilization. Actual employer expenses also depend on PBM contracts, negotiated discounts, rebates, and employee cost-sharing.
3. How can HR reduce GLP-1 costs without eliminating coverage?
HR teams can explore transparent PBM pricing, clinically appropriate prior authorization, preferred formularies, integrated healthcare programs, alternative purchasing arrangements, and ongoing utilization monitoring.
4. Can an employer cover GLP-1 drugs for diabetes but not weight loss?
Yes, many employer health plans distinguish between medical indications when determining coverage. However, plan rules should be clearly documented and reviewed for compliance with applicable laws and coverage requirements.
5. How often should HR review GLP-1 prescription spending?
Quarterly monitoring is useful for identifying unexpected spending or utilization trends. A more comprehensive annual review can help employers make decisions about benefits design, vendor contracts, and future coverage.
